Vnitr Lek 2022, 68(6):376-386 | DOI: 10.36290/vnl.2022.078

Comprehensive approach to a patient with arterial hypertension and dyslipidemia

Zdeněk Ramík1, 2, Jan Václavík1, 2, Pavla Jadrníčková1, Jana Obrová3, Janula Stromská1
1 Interní a kardiologická klinika, Fakultní nemocnice Ostrava
2 Lékařská fakulta Ostravské univerzity
3 I. interní klinika - kardiologická, Fakultní nemocnice Olomouc

Arterial hypertension together with dyslipidemia, diabetes and smoking are the most severe risk factors for cardiovascular (CV) disease. The Czech Republic is among the countries with a high risk of cardiovascular disease. To reduce cardiovascular mortality and morbidity in our patients, a comprehensive approach to treatment and, in most cases, aggressive control of all risk factors is needed. This article summarizes current diagnostic and therapeutic procedures for arterial hypertension and dyslipidaemia, as well as the concept of vascular age, which can help us to communicate CV risk with patients.

Keywords: arterial hypertension, dyslipidemia, vascular age, vascular memory.

Accepted: September 23, 2022; Published: October 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ramík Z, Václavík J, Jadrníčková P, Obrová J, Stromská J. Comprehensive approach to a patient with arterial hypertension and dyslipidemia. Vnitr Lek. 2022;68(6):376-386. doi: 10.36290/vnl.2022.078.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Visseren JLF, Mach F, Smulders MY et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. Volum. 2021;42(34):3227-3337. Go to original source... Go to PubMed...
    2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 Go to original source... Go to PubMed...
    3. Táborský M., Vrablík M. Prevence kardiovaskulárních onemocnění. Doporučený diagnostický a terapeutický postup pro všeobecné praktické lékaře 2022.
    4. Williams B, Mancia G, Spiering W et. Al. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), European Heart Journal. 2018;39(33):3021-3104. Go to original source... Go to PubMed...
    5. Vráblík M, Piťha J, Blaha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Hypertenze a KV prevence 2019;2:68-77. Go to original source...
    6. Václavík J. Obtížně léčitelná hypertenze. Druhé vydání. Praha: Mladá fronta, 2017. 134 s. ISBN 978-80204-4421-9.
    7. Ramík Z., Václavík J. Valsartan: možnosti preskripce v ordinaci praktického lékaře. Acta medicinae 2021;15:56-58.
    8. Hatala R, Pella D, Hatalová K et al. Optimization of Blood Pressure Treatment with Fixed‑Combination Perindopril/Amlodipine in Patients with Arterial Hypertension. Clin Drug Investig 2012;32(9):603-612. Go to original source...
    9. Wald S et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11,000 participants from 42 trials. Ann. Int. Med. 2009.
    10. Parati G et al. Adherence to Single‑Pill Versus Free‑Equivalent Combination Therapy in Hypertension. Hypertension2021;77:692-705. Go to original source... Go to PubMed...
    11. Cuende JI et al. European Heart Journal (2010) 31, 2351-2358. doi:10.1093/eurheartj/ehq205 Go to original source... Go to PubMed...
    12. Gupta A, Mackay J, Whitehouse A et al. Long‑term mortality after blood pressure‑lowering and lipid‑lowering treatment in patients with hypertension in the Anglo‑Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow‑up results of a randomised factorial trial. Lancet. 2018;392(10153):1127-1137. doi:10.1016/S0140-6736(18)31776-8. Go to original source... Go to PubMed...
    13. Olsen MH, Angell SY, Asma S et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016;388:2665-2712. Go to original source... Go to PubMed...
    14. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin-Angiotensin-Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Press Cardiovasc Prev. 2018;25(2):137-145. doi:10.1007/s40292-018-0252-5. Go to original source... Go to PubMed...
    15. Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long‑term effects of Ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation. 2005;112(9):1339-1346. Go to original source... Go to PubMed...
    16. Kostis WJ, Thijs L, Richart T et al. Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure‑Lowering Medication. Hypertension. 2010;56:1060-1068. Go to original source... Go to PubMed...
    17. Cífková R. Co přinášejí nové tabulky SCORE. [Rozhovor] Oficiální kongresové zpravodajství České kardiologické společnosti. Dostupné z WWW: https://cks22.ckstv.cz/
    18. Lopez‑Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015 Mar;22(3):389-96. Go to original source... Go to PubMed...
    19. Parati G et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension 2021;77:692-705 Go to original source... Go to PubMed...
    20. Wald S et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Ann. Int. Med. 2009 Go to original source... Go to PubMed...
    21. SPC - souhrn údajů o přípravku Lipertance, datum revize textu 22.7.2022, www.sukl.cz.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.